Vepafestinib inhibited the growth of multiple lung cancer patient-derived cell lines harboring RET fusions with different N-terminal partners (CCDC6, KIF5B, TRIM33) and an RETC634W mutation–positive MTC cell line and was active in a number of NSCLC xenograft models. Here, RET is linked to non-small cell lung carcinoma.